News Column

Reports Outline Lung Cancer Findings from Florida A&M University

February 12, 2014



By a News Reporter-Staff News Editor at Biotech Week -- A new study on Oncology is now available. According to news reporting from Tallahassee, Florida, by NewsRx journalists, research stated, "The purpose of the present study was to evaluate the effect of Telmisartan (Tel) and Losartan (Los) on nanoparticle intratumoral distribution and anticancer effects in lung cancer. A549 lung tumor cells were orthotopically and metastatically administered to Nu/nu mice."

The news correspondents obtained a quote from the research from Florida A&M University, "Fluorescent polystyrene nanoparticles (FPNPs, size similar to 200 nm) beads were used to study their intratumoral distribution after Tel and Los treatments. Animals were administered with FPNPs and after 2 h, FPNPs intratumoral distribution was studied by fluorescent microscopy. Tel (similar to 1.12 mg/kg) and Los (similar to 4.5 mg/kg) were administered by inhalation delivery at alternative days for 4 weeks to tumor bearing animals. Collagen-1, transforming growth factor beta 1 (TGF-beta 1), cleaved caspase-3, Vimentin and E-Cadherin expressions were studied by western blotting. To correlate the AT(1) receptor blockage to anticancer effects, VEGF levels and microvessel densities (MVD) were quantified. Los and Tel treated group resulted in the 5.33 and 14.33 fold increase respectively in the FPNPs intratumoral distribution as compared to the controls. Tel treatment attenuated 2.23 and 1.70 fold Collagen 1 expression compared to untreated control and Los groups, respectively. Further, in Tel and Los treated groups, the TGF-beta 1 active levels were significantly (p < 0.05) decreased. Tel (at four times less dose) was 1.89 and 1.92 fold superior in anticancer activity to Los respectively in A549 orthotopic and metastatic tumor models (p < 0.05) when given by inhalation route."

According to the news reporters, the research concluded: "Tel, by virtue of its dual pharmacophoric nature could be an ideal candidate for combination therapy to improve the nanoparticle intratumoral distribution and anticancer effects. ."

For more information on this research see: Inhalation delivery of Telmisartan enhances intratumoral distribution of nanoparticles in lung cancer models. Journal of Controlled Release, 2013;172(1):86-95. Journal of Controlled Release can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; Journal of Controlled Release - www.elsevier.com/wps/product/cws_home/502690)

Our news journalists report that additional information may be obtained by contacting C. Godugu, Florida A&M Univ, Div Res Anim Welf & Res Integr, Tallahassee, FL 32307, United States. Additional authors for this research include A.R. Patel, R. Doddapaneni, S. Marepally, T. Jackson and M. Singh (see also Oncology).

Keywords for this news article include: Florida, Oncology, Tallahassee, Lung Cancer, Nanoparticle, United States, Lung Neoplasms, Nanotechnology, Combination Therapy, Emerging Technologies, North and Central America

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools